Drew Deniger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Drew Deniger has a total of 123 co-authors. Here are the top co-authors by number of shared publications:
- Alex M. Jaeger
H. Lee Moffitt Cancer Center & Research Institute
22 shared publications - Alexandre Reuben
Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center
22 shared publications - Amanda Montoya
Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
22 shared publications - Ara A. Vaporciyan
Department of Thoracic and Cardiovascular Surgery, MD Anderson Cancer Center, Houston, TX, USA
22 shared publications - Aria Vaishnavi
The University of Texas MD Anderson Cancer Center 1 Department of Thoracic/Head & Neck Medical Oncology Houston, Texas
22 shared publications - Barbara Nassif Rausseo
Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA
22 shared publications
Latest Publications
- Open Access
- 11 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from FOXM1-Specific TCR-Engineered T Cells Target Non–Small Cell Lung Cancer
Supplementary Figure 1. FOXM1 is minimally expressed in healthy organs.
- 11 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from FOXM1-Specific TCR-Engineered T Cells Target Non–Small Cell Lung Cancer
Supplementary Figure 1. FOXM1 is minimally expressed in healthy organs.
- Open Access
- 11 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from FOXM1-Specific TCR-Engineered T Cells Target Non–Small Cell Lung Cancer
Supplementary Figure 2. FOXM1 epitopes are eluted on H1975.
- 11 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from FOXM1-Specific TCR-Engineered T Cells Target Non–Small Cell Lung Cancer
Supplementary Figure 2. FOXM1 epitopes are eluted on H1975.
- Open Access
- 11 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from FOXM1-Specific TCR-Engineered T Cells Target Non–Small Cell Lung Cancer
Supplementary Figure 3. FOXM1-specific T cell phenotyping.
- 11 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from FOXM1-Specific TCR-Engineered T Cells Target Non–Small Cell Lung Cancer
Supplementary Figure 3. FOXM1-specific T cell phenotyping.
- Open Access
- 11 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from FOXM1-Specific TCR-Engineered T Cells Target Non–Small Cell Lung Cancer
Supplementary Figure 4. FOXM1-specific TCR-T sustain Tem phenotype while upregulating checkpoint molecules upon antigen exposure.
- 11 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from FOXM1-Specific TCR-Engineered T Cells Target Non–Small Cell Lung Cancer
Supplementary Figure 4. FOXM1-specific TCR-T sustain Tem phenotype while upregulating checkpoint molecules upon antigen exposure.
- Open Access
- 11 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from FOXM1-Specific TCR-Engineered T Cells Target Non–Small Cell Lung Cancer
Supplementary Figure 6. FOXM1-restricted TCR-T cells are specific.
- 11 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from FOXM1-Specific TCR-Engineered T Cells Target Non–Small Cell Lung Cancer
Supplementary Figure 6. FOXM1-restricted TCR-T cells are specific.
- Open Access
- 11 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from FOXM1-Specific TCR-Engineered T Cells Target Non–Small Cell Lung Cancer
Supplementary Figure 7. FOXM1-specific TCR-T do not lead to toxicity in vivo.
- 11 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from FOXM1-Specific TCR-Engineered T Cells Target Non–Small Cell Lung Cancer
Supplementary Figure 7. FOXM1-specific TCR-T do not lead to toxicity in vivo.
- Open Access
- 11 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from FOXM1-Specific TCR-Engineered T Cells Target Non–Small Cell Lung Cancer
Supplementary Figure 5. TCR-T cells lack recognition of normal tissue cell lines.
- 11 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from FOXM1-Specific TCR-Engineered T Cells Target Non–Small Cell Lung Cancer
Supplementary Figure 5. TCR-T cells lack recognition of normal tissue cell lines.
- Open Access
- 11 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from FOXM1-Specific TCR-Engineered T Cells Target Non–Small Cell Lung Cancer
Supplementary Table 1. Predicted peptides with corresponding HLA alleles.
- 11 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from FOXM1-Specific TCR-Engineered T Cells Target Non–Small Cell Lung Cancer
Supplementary Table 1. Predicted peptides with corresponding HLA alleles.
- Open Access
- 11 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from FOXM1-Specific TCR-Engineered T Cells Target Non–Small Cell Lung Cancer
Supplementary Figure 8. FOXM1 TCR-T cells are detectable in the periphery.
- 11 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from FOXM1-Specific TCR-Engineered T Cells Target Non–Small Cell Lung Cancer
Supplementary Figure 8. FOXM1 TCR-T cells are detectable in the periphery.
- Open Access
- 11 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 9 from FOXM1-Specific TCR-Engineered T Cells Target Non–Small Cell Lung Cancer
Supplementary Figure 9. FOXM1 TCR-T cells are detectable in the periphery at time of sacrifice.
- 11 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 9 from FOXM1-Specific TCR-Engineered T Cells Target Non–Small Cell Lung Cancer
Supplementary Figure 9. FOXM1 TCR-T cells are detectable in the periphery at time of sacrifice.